LM Advisors’s Bristol-Myers Squibb BMY Stock Holding History

LM Advisors’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-44	Closed	-$2.26K	–	273
2023 Q4	$2.26K	Buy	+44	New	+$2.31K	﹤0.01%	654

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LM Advisors's BMY Position: Q1 2024 in Review

LM Advisors sold out of Bristol-Myers Squibb (BMY) in Q1 2024, closing a stake of 44 shares — an estimated $2.26K sold.

LM Advisors first reported a position in BMY in Q4 2023 and held it in 1 quarter. The position peaked at $2.26K in Q4 2023. 2,339 funds tracked by Wall St. Rank hold BMY as of Q1 2024.

LM Advisors reported no remaining Bristol-Myers Squibb position as of Q1 2024 after selling out during the quarter.
LM Advisors sold 44 Bristol-Myers Squibb shares in Q1 2024, an estimated $2.26K.
LM Advisors first reported a position in Bristol-Myers Squibb in Q4 2023 and held it in 1 quarter.
LM Advisors's Bristol-Myers Squibb position peaked at $2.26K in Q4 2023.
2,339 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2024.

Based on LM Advisors's 13F filing for Q1 2024, filed 15 May 2024.